Precision biosciences inc stock.

Precision BioSciences Annual Revenue Estimates (Precision BioSciences) The company’s market cap is about $152M, so that would be a roughly 0.3x forward price-to-sales. Considering the industry ...3 equities research analysts have issued 1 year price targets for Precision BioSciences' stock. Their DTIL share price targets range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price.(RTTNews) - Neurocrine Biosciences Inc (NBIX) announced a profit for first quarter that decreased from last year and missed the Street estimates.... (RTTNews) - Neurocrine Biosciences Inc (NBIX) announced a profit for first quarter that de...Jun 27, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ...

November 28, 2023. DURHAM, N.C. -- (BUSINESS WIRE)--Nov. 28, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,...

Aug 15, 2023 · DURHAM, N.C., August 15, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today ... View the latest Precision Biosciences Inc. (DTIL) stock price, news, historical charts, analyst ratings and financial information from WSJ.

View 13F filing holders of Precision BioSciences Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers.Precision BioSciences, Inc. | 18,265 followers on LinkedIn. Dedicated to Improving Life. | Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company …Jun 21, 2022 · Precision BioSciences Announces $50 Million Offering of Common Stock. June 21, 2022 05:25 PM Eastern Daylight Time. DURHAM, N.C.-- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a ... Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Find out why I rate DTIL stock a Buy.Web

DURHAM, N.C.--(BUSINESS WIRE)--Aug. 15, 2023-- Precision BioSciences, Inc. ... including fluctuations in our stock price, and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, ...

See the latest Precision BioSciences Inc stock price (DTIL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary …Tesla’s stock is predicted to increase in value in 2015, according to Forbes. In January 2015, Forbes noted that Tesla Motors, Inc.Currently, the analyst consensus on Precision BioSciences is a Moderate Buy with an average price target of $10.50. See today’s best-performing stocks on TipRanks >> The company has a one-year ...WebDec 1, 2023 · 3 equities research analysts have issued 1 year price targets for Precision BioSciences' stock. Their DTIL share price targets range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price. Precision Biosciences Inc. Watch list NEW Set a price target alert Open Last Updated: Dec 1, 2023 9:53 a.m. EST Real time quote $ 0.3645 0.0094 2.65% Previous Close $0.3551 Advanced Charting... About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ...

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.On Monday, Precision Biosciences Inc [NASDAQ:DTIL] saw its stock fall -6.04% to $0.40. On the same session, the stock had its day’s lowest price of $0.3921, but rose to a high of $0.4395. Over the last five days, the stock has gained 29.21%. Precision Biosciences Inc shares have fallen nearly -66.39% since the year began.Get the latest Precision BioSciences, Inc. (DTIL) stock news and headlines to help you in your trading and investing decisions.Precision BioSciences Inc. is based in Durham, North Carolina. Stock Name, Country, Market Cap, PE Ratio. Amgen (AMGN), United States, $142.010B, 14.72. Bristol ...Weighted average shares of common stock outstanding were approximately 110.8 million for the quarter ended September 30, 2022, as compared to approximately 59.7 million for the quarter ended September 30, 2021. ... Precision BioSciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per …Find the latest Precision BioSciences, Inc. (DTIL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Precision BioSciences, Inc. 302 East Pettigrew Street Suite A-100 Durham, NC 27701 United States 919 314 5512 https://www.precisionbiosciences.com Sector(s) : Healthcare Industry : Biotechnology ...

Precision BioSciences to Report Third Quarter Results on November 7, 2023. DURHAM, N.C., November 01, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it will publish ... Precision BioSciences (DTIL Quick Quote DTIL - Free Report) has been on a downward spiral lately with significant selling pressure. After declining 27.5% over the past four weeks, the stock looks ...Real time Precision BioSciences (DTIL) stock price quote, stock graph, ... Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies ...WebDec 1, 2023 · The short interest in Precision Biosciences Inc (NASDAQ:DTIL) is 0.85 million shares and it means that shorts have 0.83 day (s) to cover. The consensus price target of analysts on Wall Street is $2.63, which implies an increase of 86.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 ... In June 2022, Precision announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, ... Precision Biosciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts)View the latest Precision Biosciences Inc. (DTIL) stock price, news, historical charts, analyst ratings and financial information from WSJ.Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. ... The increase in weighted average shares of common …WebDURHAM, N.C., April 20, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies ...Individuals with disabilities: if you are a qualified individual with a disability and are unable or limited in your ability to use or access the online application system process due to your disability, please contact our disability applications assistant at 919-314-5512 to request assistance. Precision BioSciences provides reasonable ...DURHAM, N.C.--(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of …

Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is ...

Precision BioSciences, Inc. (Nasdaq: ... as an inducement for the employee to commence service with Precision. The stock option has a per share exercise price equal to the fair market value of Precision’s Common Stock on the grant date, which was equal to $0.42. The stock option has a 10-year term and vests …

Stock Price Forecast The 4 analysts offering 12-month price forecasts for Precision BioSciences Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.00. Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.List Alan, the Chief Medical Officer of Precision Biosciences Inc, sale 7,771 shares at $0.79 during a trade that took place back on Apr 27, which means that List Alan is holding 56,496 shares at $6,139 based on the most recent closing price. Stock Fundamentals for DTIL. Current profitability levels for the company are sitting at:Get Precision BioSciences Inc (DTIL.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsPrecision BioSciences, Inc. (Nasdaq: ... as an inducement for the employee to commence service with Precision. The stock option has a per share exercise price equal to the fair market value of Precision’s Common Stock on the grant date, which was equal to $0.42. The stock option has a 10-year term and vests …Precision BioSciences GAAP EPS of -$0.46 misses by $0.05, revenue of $3.82M misses by $1.29M SA News Mon, Aug. 08, 2022 Precision BioSciences Q2 2022 Earnings PreviewDURHAM, N.C.--(BUSINESS WIRE)--Jul. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it has received final meeting minutes from its recent Type B End of Phase 1 meeting with the U.S. Food and Drug Administration (FDA) for its lead ...DURHAM - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced financial results for the second quarter ended June 30, 2023 and provided a business update. 'The first half of 2023 has been a busy time at …Precision BioSciences, Inc. Common Stock (DTIL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

Precision BioSciences last posted its earnings results on November 7th, 2023. The reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The business earned $13.12 million during the quarter, compared to the consensus estimate of $7.50 million.CAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically defined diseases ...Yu: Precision BioSciences: Current Employment, Current equity holder in publicly-traded company. Heery: Precision BioSciences: Current equity holder in publicly-traded company, Ended employment in the past 24 months; Arcellx: Current Employment, Current holder of stock options in a privately-held company.Precision BioSciences, Inc. | 18,265 followers on LinkedIn. Dedicated to Improving Life. | Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo ...Instagram:https://instagram. prudential dividendsbuying nfts1964 us kennedy half dollar valuef a a n g Nov 29, 2023 eww etfrarest quarters in the world Get Our Latest Stock Report on Precision BioSciences. Precision BioSciences Stock Performance. NASDAQ:DTIL traded up $0.01 during trading on Monday, reaching $0.38. The company’s stock had a ...WebStock Price Forecast The 4 analysts offering 12-month price forecasts for Precision BioSciences Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.00. www.lcid stock p Jun 27, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ... Nov 24, 2023 · With Precision Biosciences stock trading at $0.41 per share, the total value of Precision Biosciences stock (market capitalization) is $49.24M. Precision Biosciences stock was originally listed at a price of $17.44 in Mar 28, 2019. If you had invested in Precision Biosciences stock at $17.44, your return over the last 4 years would have been ... The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.